New Issue: UBS prices $106,000 buffered return optimization securities linked to Teva Pharmaceutical

New York, Feb. 21 – UBS AG, London Branch priced $106,000 of buffered return optimization securities due Feb. 26, 2020 linked to Teva Pharmaceutical Industries Ltd. stock, according to a 424B2 filing with the Securities and Exchange Commission.

If Teva Pharmaceutical stock closes at or above its initial price, the payout at maturity will be par plus five times any gain, capped at par plus 18%.

If Teva Pharmaceutical stock declines by up to 10%, the payout will be par. Investors will be exposed to any losses beyond 10%.

The agent is UBS Financial Services Inc. and UBS Investment Bank.

Issuer:	UBS AG, London Branch
Issue:	Buffered return optimization securities
Underlying stock:	Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
Amount:	$106,000
Maturity:	Feb. 26, 2020
Coupon:	0%
Price:	Par of $10
Payout at maturity:	Par plus five times return of Teva Pharmaceutical stock, capped at 18%; par if stock declines by up to 10%; exposure to losses beyond 10%
Initial share price:	$17.25
Pricing date:	Feb. 21
Settlement date:	Feb. 25
Agents:	UBS Financial Services Inc. and UBS Investment Bank
Fees:	2%
Cusip:	90286R387

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.